AEMD Logo

Aethlon Medical, Inc. (AEMD) 

NASDAQ$0.3736
Market Cap
$5.4M
Sector
Healthcare
Industry
Medical—Devices
Rank in Sector
426 of 924
Rank in Industry
54 of 118

AEMD Insider Trading Activity

AEMD Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$00–
Sells
$00–

Related Transactions

No records found

About Aethlon Medical, Inc.

Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.

Insider Activity of Aethlon Medical, Inc.

Over the last 12 months, insiders at Aethlon Medical, Inc. have bought $0 and sold $0 worth of Aethlon Medical, Inc. stock.

On average, over the past 5 years, insiders at Aethlon Medical, Inc. have bought $0 and sold $56,580 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

List of Insider Buy and Sell Transactions, Aethlon Medical, Inc.

2020-12-17SaleShah Chetandirector
26,852
0.2008%
$2.11$56,580+15.02%
2010-04-13SaleBROENNIMAN EDWARD Gdirector
9,800
0.015%
$0.34$3,283-26.47%
2010-04-12SaleBROENNIMAN EDWARD Gdirector
25,000
0.0383%
$0.34$8,375-26.47%
2010-04-09SaleBROENNIMAN EDWARD Gdirector
25,000
0.0381%
$0.33$8,338-26.47%
2010-04-08SaleBROENNIMAN EDWARD Gdirector
25,000
0.0383%
$0.34$8,375-26.47%
2010-04-07SaleBROENNIMAN EDWARD Gdirector
24,000
0.0395%
$0.35$8,400-24.24%
2010-04-07SaleBARRY FRANKLYN S JRdirector
8,800
0.0145%
$0.35$3,080-24.24%
2010-04-06SaleBROENNIMAN EDWARD Gdirector
23,800
0.0359%
$0.35$8,330-30.56%
2010-04-06SaleBARRY FRANKLYN S JRdirector
23,800
0.0359%
$0.35$8,330-30.56%
2010-04-05SaleBROENNIMAN EDWARD Gdirector
23,000
0.0348%
$0.35$8,073-30.56%
2010-04-05SaleBARRY FRANKLYN S JRdirector
23,000
0.0348%
$0.35$8,073-30.56%
2010-04-01SaleBROENNIMAN EDWARD Gdirector
22,800
0.0354%
$0.37$8,436-32.43%
2010-04-01SaleBARRY FRANKLYN S JRdirector
22,800
0.0354%
$0.37$8,436-32.43%
2010-03-31SaleBROENNIMAN EDWARD Gdirector
22,000
0.0328%
$0.36$8,030-34.21%
2010-03-31SaleBARRY FRANKLYN S JRdirector
22,000
0.033%
$0.37$8,074-34.21%
2010-03-30SaleBROENNIMAN EDWARD Gdirector
22,000
0.041%
$0.38$8,360-30.56%
2010-03-30SaleBARRY FRANKLYN S JRdirector
22,000
0.0404%
$0.37$8,239-30.56%
2010-03-29SaleBROENNIMAN EDWARD Gdirector
22,000
0.0384%
$0.39$8,470-35.90%
2010-03-29SaleBARRY FRANKLYN S JRdirector
22,000
0.0377%
$0.38$8,327-35.90%
2010-03-26SaleBROENNIMAN EDWARD Gdirector
20,000
0.0362%
$0.41$8,200-37.50%
Total: 43

AEMD Institutional Investors: Active Positions

Increased Positions12+52.17%1M+305.83%
Decreased Positions7-30.43%39,414-9.72%
New Positions9New1MNew
Sold Out Positions5Sold Out35,330Sold Out
Total Postitions28+21.74%2M+296.11%

AEMD Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Ikarian Capital, Llc$389.005.36%750,000+750,000New2024-12-31
Ubs Group Ag$129.001.78%249,535+31,282+14.33%2024-12-31
Boothbay Fund Management, Llc$112.001.55%216,600+216,600New2024-12-31
Geode Capital Management, Llc$57.000.79%110,333+11,939+12.13%2024-12-31
Virtu Financial Llc$49.000.67%94,173+94,173New2024-12-31
Sassicaia Capital Advisers Llc$19.000.26%36,000+36,000New2024-12-31
Allegiance Financial Group Advisory Services Llc$16.000.21%30,000+30,000New2024-12-31
Renaissance Technologies Llc$15.000.21%29,307+29,307New2024-12-31
Scientech Research Llc$12.000.16%22,594+22,594New2024-12-31
Two Sigma Investments, Lp$12.000.16%22,556+7,120+46.13%2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Analyst Recommendations

Analyst Price Targets

No data is available at this moment.
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.